Repligen Corp (NAS:RGEN)
$ 168.49 -3.29 (-1.92%) Market Cap: 9.41 Bil Enterprise Value: 9.55 Bil PE Ratio: 673.96 PB Ratio: 4.77 GF Score: 93/100

Repligen Corp at UBS Global Healthcare Conference Transcript

May 21, 2019 / 02:30PM GMT
Release Date Price: $68.94 (+2.50%)
Daniel Gregory Brennan;Anthony J. Hunt
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences;Repligen Corporation -

Great. Welcome, my name is Dan Brennan, to Day 2 of UBS Global Healthcare Conference. Really pleased that everyone is here. I cover life science, tools, diagnostics and pharma services. Pleased to be joining on stage with CEO of Repligen Corporation, Tony Hunt. And in the audience, we have Sondra Newman.

We're going to have a breakout after this at the Alvin-Carnegie room. Before we start, just I want to refer you to the UBS website, www.com or ubs -- excuse me, www.ubs.com where you can view the analyst disclaimers.

So with that, Tony, I don't know if you want to -- I've a series of questions and well, I'll try to seek audience participation certainly. We have more than enough to go through, but feel free to jump, and I'll look up periodically. Tony, I don't know if you want to may be make some opening comments and then we can dig in.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot